Healthcare Billing Services in Pennsylvania

Medical billing costs vary according to the services involved, claim complexity, practice workflow, payer mix, infusion or OPAT activity, and whether support is full-service or limited to overflow, denials, authorization, or A/R work. GrowInfectiousDisease does not publish invented rates or generalized margins. Practices can use their own numbers and the available guidance to evaluate costs, revenue streams, and financial sustainability.

Support may address claims management, coding review, claim scrubbing, rejection clearing, denial appeals, eligibility and authorization, payment reconciliation, underpayment review, A/R follow-up, payer contract compliance, credentialing, reporting, and workflow improvement. These services reflect the distinct needs of infectious disease practices handling office visits, hospital consults, infusion, drug claims, and OPAT programs.

Yes. Infectious disease revenue-cycle work can include infusion and OPAT workflows, including eligibility, prior authorization, medical-versus-pharmacy benefit review, drug and administration billing, claims submission, denials, underpayments, and A/R follow-up. The appropriate scope depends on the practice’s service lines, systems, staffing, and current workflow gaps.

Denials are categorized by root cause, such as drug or administration coding, missing authorization, medical-versus-pharmacy benefit confusion, or under-documented consults. Payer-specific appeals can then be prepared with clinical documentation. Findings should also be shared with clinical, coding, and front-office teams so recurring problems are addressed in the workflow rather than repeatedly appealed.

Revenue can be lost before a claim is submitted through under-leveled visits, missed drug or administration charges, incomplete documentation, authorization gaps, and workflow breakdowns. It can also be lost after submission through denials, underpayments, contract issues, and aging balances. Reporting by payer, service line, and provider helps trace leakage to documentation, charge capture, or contract causes.

Payment reconciliation can compare payments with expected reimbursement for drug, administration, and E/M claims. Reviews may identify short-pays, incorrect fee schedule application, and unit or NDC mismatches. Underpayments can then be disputed and tracked to recovery, while the findings may inform payer discussions and contract renewal decisions.

Yes. Payer contract and coverage-agreement review can examine reimbursement for drugs, infusion administration, and consult services. It may also consider hospital coverage and stewardship agreements, where infectious disease work can be delivered with limited or no direct payment. The objective is to identify potential compliance issues and terms that may warrant attention during renewal.

Yes. GrowInfectiousDisease provides browser-based tools, financial models, and plain-English explanations that let practices apply their own numbers. The resource does not rely on invented rates, drug acquisition costs, payment rates, or margin figures. This approach helps users examine revenue streams, operational decisions, and sustainability in the context of their own practice.